Posted by Michael Wonder on 20 Aug 2021
TGA provisionally approves GlaxoSmithKline's COVID-19 treatment sotrovimab (Xevudy)
20 August 2021 - Today, the Therapeutic Goods Administration granted provisional approval to GSK for its COVID-19 treatment - sotrovimab (Xevudy) - making it the second COVID-19 treatment to receive regulatory approval in Australia.
Australia is the first OECD country to issue a formal regulatory approval for sotrovimab (Xevudy).
